Psoriatic Arthritis
Conference Coverage
Apremilast’s positive study results made it the talk of ACR 2013
Major finding: After 16 weeks of treatment, the investigational drug apremilast achieved an ACR20 response of 29.2% at 20 mg twice daily as first-...
Conference Coverage
Treat-to-target approach for psoriatic arthritis found beneficial
Major finding: At 48 weeks, a higher proportion of psoriatic arthritis patients in the intensive management group achieved ACR70, compared with...
News
Ustekinumab approved for psoriatic arthritis
Conference Coverage
Apremilast effects sustained at 1 year in psoriatic arthritis
Major finding: ACR 20 response at 1 year was 57%-63% for patients given apremilast.Data source: PALACE 1, a 504-patient, phase III, multicenter,...